PRODUCT LITERATURE

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial

---

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a potentially disabling autoimmune disease causing progressive or relapsing–remitting weakness with or without sensory loss. Previous small trials demonstrated short-term benefit from intravenous immunoglobulin (IVIg), and international guidelines recommend IVIg as an option. However, evidence had been insufficient to persuade authorities to approve IVIg for use in CIDP. This article aims to review the Immune Globulin Intravenous CIDP Efficacy (ICE) trial, which was a randomized, double-blind, placebo-controlled, response-conditional crossover trial of Gamunex® (intravenous immunoglobulin, 10% caprylate/chromatography purified). With 117 participants, it is the largest treatment trial ever conducted in CIDP. The results showed unequivocal short- and long-term benefit from IVIg in confirmation of previous reports. The trial also showed for the first time that continued IVIg infusion 1 g/kg every 3 weeks protected participants from relapse

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

TEXTBOOK

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Privigen
intravenous immunoglobulin
chronic inflammatory demyelinating polyradiculoneu
the ICE trial

Specific Detail Info

Expert Review of Neurotherapeutics 2009;9(6):789-95

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment